ABSTRACT
BACKGROUND: The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma. METHODS: Patients with anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma multiforme, or gliosarcoma received radiation therapy plus BCNU as initial therapy. Subsequently, patients without tumor progression at the completion of radiation therapy were stratified by age, extent of surgery, tumor grade and histology, Eastern Cooperative Oncology Group performance status, and treating institution, and then were randomly assigned to receive either BCNU alone (200 mg/m(2) on Day 1) or BCNU (150 mg/m(2) on Day 3) plus IFN--alpha (12 million U/m(2) on Days 1-3, Weeks 1, 3, and 5) every 7 weeks for a maximum of 6 cycles. RESULTS: Of the 383 patients enrolled in the study, 275 eligible patients were randomized. There was no significant difference with regard to time to disease progression or overall survival between the two groups. Patients receiving IFN-alpha experienced more fever, chills, myalgias, and neurocortical symptoms including somnolence, confusion, and exacerbation of neurologic deficits. Cox multivariate regression models confirmed known favorable prognostic variables including younger age, Grade 3 tumor (according to World Health Organization criteria), and greater extent of surgery. Cox and classification and regression tree analysis models also demonstrated that a normal baseline Folstein mini-mental status examination (MMSE) score was associated with better prognosis. CONCLUSIONS: IFN-alpha does not appear to improve time to disease progression or overall survival in patients with high-grade glioma and appears to add significantly to toxicity. The baseline MMSE score may serve as an independent prognostic factor and warrants further investigation.
Subject(s)
Antineoplastic Agents, Alkylating/pharmacology , Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Carmustine/pharmacology , Glioma/drug therapy , Glioma/radiotherapy , Interferon-alpha/pharmacology , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents, Alkylating/administration & dosage , Brain Neoplasms/pathology , Carmustine/administration & dosage , Combined Modality Therapy , Disease Progression , Female , Glioma/pathology , Humans , Interferon-alpha/administration & dosage , Male , Middle Aged , Neoplasm Staging , Survival Analysis , Treatment OutcomeABSTRACT
Current systemic treatment options for patients with relapsed gliomas are limited. The topoisomerase I inhibitor topotecan has demonstrated broad antitumor activity in both preclinical studies as well as a number of phase I and II trials in humans. Studies in primates have shown good cerebrospinal fluid levels of topotecan following systemic administration. We therefore performed this phase II trial in patients who developed evidence of progressive glioma after definitive radiation therapy. Patients were treated with 1.5 mg/m2 intravenously daily for 5 consecutive days repeated every three weeks. For patients who had received prior nitrosourea-containing chemotherapy, the starting dose was 1.25 mg/m2. Thirty-three patients were entered on this study. All patients were eligible and evaluable for both response and toxicity. Seven patients experienced grade 4 leukopenia with 2 of these patients dying of infection-related complications. Six of these seven patients were not taking anticonvulsants during treatment. Nine patients developed grade 3-4 thrombocytopenia, seven of whom were not taking anticonvulsants. Nonhematologic side effects were infrequent and manageable. One patient experienced a partial response to this treatment for an overall response rate of 3% (95% binomial confidence interval 0.3%-20.4%). The median time to progression was 14.9 weeks and median survival 19.9 weeks. Topotecan at this dose and schedule showed no substantial activity in relapsed gliomas.
Subject(s)
Antineoplastic Agents/therapeutic use , Glioma/drug therapy , Topotecan/therapeutic use , Adult , Aged , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Topotecan/adverse effectsABSTRACT
PURPOSE: This study was an open label, randomized Phase 3 trial in newly diagnosed patients with anaplastic glioma comparing radiotherapy plus adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy with or without bromodeoxyuridine (BUdR) given as a 96-hour infusion each week of radiotherapy. METHODS AND MATERIALS: Only patients 18 years or older with newly diagnosed anaplastic glioma were eligible; central pathology review was accomplished, but was not mandated prior to registration. The study had initially opened as a Northern California Oncology Group (NCOG) trial in 1991, becoming an Intergroup RTOG, SWOG, and NCCTG study in July 1994. Total accrual of 293 patients was planned as the sample size, using survival and time to tumor progression as the primary endpoints. The experiment arm (RT/BUdR plus PCV) was to be compared to the control arm (RT plus PCV) using an alpha = 0.05, one-tailed, with a power of 85% for detecting an increase in median survival from 160 to 240 weeks, assuming a 3-year follow-up after completion of enrollment. RESULTS: As of July 1996, 281 patients had been randomized; 53 (20%) were ineligible, primarily based upon central pathology review, and another 39 cases were canceled. In total, 30% of cases were excluded from analysis. The treatment arms were well balanced despite this rate of exclusion. The RTOG Data Monitoring Committee recommended suspension of enrollment in July 1996 based upon a stochastic curtailment analysis which strongly suggested that the addition of BUdR would not be associated with increased survival. In February 1997, the study was closed prior to full enrollment. At that time, the 1-year survival estimates were 82% versus 68% for RT plus PCV and RT/BUdR plus PCV respectively (one-sided, p = 0.96). The conditional power analysis indicated that even with an additional 12 months of additional accrual and follow-up the probability of detecting the prespecified difference was less than 0.01%. The differences in the two arms seem to be due to early deaths in the BUdR arm, not related to toxicity of the treatment. CONCLUSIONS: Despite encouraging Phase 2 results with BUdR, it is unlikely that a survival benefit will be seen. A final study analysis will not be done for at least 3 more years.
Subject(s)
Astrocytoma/radiotherapy , Brain Neoplasms/radiotherapy , Bromodeoxyuridine/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Astrocytoma/drug therapy , Astrocytoma/mortality , Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Chemotherapy, Adjuvant , Disease Progression , Female , Humans , Lomustine/administration & dosage , Male , Middle Aged , Procarbazine/administration & dosage , Proportional Hazards Models , Survival Analysis , Vincristine/administration & dosageABSTRACT
OBJECTIVE: To assess the pharmacokinetics, toxicity, and efficacy of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261). DESIGN: We initiated a phase II trial in order to determine whether evidence of antitumor activity of A10 and AS2-1 could be documented. MATERIAL AND METHODS: Patients with anaplastic astrocytoma or glioblastoma multiforme recurring after radiation therapy were eligible for enrollment in the trial. Patients received escalating doses of A10 and AS2-1 by multiple intermittent intravenous injections with use of a portable programmable pump to the target daily dose of 1.0 g/kg for A10 and of 0.4 g/kg for AS2-1. RESULTS: Nine patients were treated, in six of whom the treatment response was assessable in accordance with protocol stipulations. No patient demonstrated tumor regression. Reversible grade 2 or 3 neurocortical toxicity, consisting of transient somnolence, confusion, and exacerbation of an underlying seizure disorder, was noted in five patients. Mean steady-state plasma concentrations of phenylacetate and phenylacetylglutamine after escalation to the target doses of A10 and AS2-1 were 177+/-101 microg/mL and 302+/-102 microg/mL, respectively. Patients who exhibited confusion tended to have higher phenylacetate levels. CONCLUSION: Although we could not confirm any tumor regression in patients in this study, the small sample size precludes definitive conclusions about treatment efficacy. Antineoplaston-related toxicity was acceptable in most patients with appropriate dose modification, although severe neurocortical toxicity may occur. Steady-state plasma concentrations of phenylacetate with use of A10 and AS2-1 were similar to those reported with use of similar doses of phenylacetate alone.
Subject(s)
Antineoplastic Agents/therapeutic use , Astrocytoma/drug therapy , Benzeneacetamides , Brain Neoplasms/drug therapy , Glioblastoma/drug therapy , Glutamine/analogs & derivatives , Phenylacetates/therapeutic use , Piperidones/therapeutic use , Adult , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacokinetics , Astrocytoma/blood , Brain Neoplasms/blood , Confusion/chemically induced , Disorders of Excessive Somnolence/chemically induced , Drug Administration Schedule , Drug Combinations , Female , Glioblastoma/blood , Glutamine/adverse effects , Glutamine/pharmacokinetics , Glutamine/therapeutic use , Humans , Injections, Intravenous , Male , Middle Aged , Patient Selection , Phenylacetates/adverse effects , Phenylacetates/pharmacokinetics , Piperidones/adverse effects , Piperidones/pharmacokinetics , Seizures/chemically induced , Severity of Illness Index , Treatment OutcomeABSTRACT
OBJECTIVE: A Phase I study was conducted to determine the safety, toxicity, and maximum tolerated dose of preirradiation chemotherapy using carmustine (BCNU) and cisplatin in the treatment of high-grade gliomas. METHODS: Patients with newly diagnosed high-grade gliomas received BCNU and cisplatin after surgery, both before and during definitive radiation therapy. Preirradiation chemotherapy consisted of an administration of 40 mg/m2 BCNU on Days 1 through 3 and 30 mg/m2 cisplatin on Days 1 through 3 and 29 through 31 and repeated at 8 weeks to coincide with the start of radiation therapy. Postradiation chemotherapy consisted of an administration of 200 mg/m2 BCNU once every 8 weeks for four cycles. Radiation therapy consisted of 160-cGy fractions administered twice daily for 15 days, yielding a total dose of 4800 cGy. Dose escalation of BCNU was planned. If hematological toxicity was mild, the dose of cisplatin was to be held constant and BCNU dose escalated to 50 mg/m2 on Days 1 through 3. RESULTS: Eighteen patients were studied. The hematological toxicity was dose-limiting. Grade 3 or 4 leukopenia occurred in each of 10 patients (56%), and Grade 3 or 4 thrombocytopenia occurred in each of 9 patients (50%). Other toxicities included anorexia (94%), nausea (83%), emesis (33%), alopecia (94%), mild ototoxicity (50%), and, in one patient, death as a result of BCNU pulmonary toxicity. The median survival time was 14 months. Objective responses occurred in 45% of the patients evaluable for response. The maximum tolerated dose of this combination was 50 mg/m2 BCNU on Days 1 through 3 and 30 mg/m2 cisplatin on Days 1 through 3 and 29 through 31 before radiation and repeated in 8 weeks to coincide with the start of radiation. CONCLUSION: This schedule of the preirradiation administration of BCNU and cisplatin with accelerated hyper-fractionated radiation therapy for the treatment of high-grade gliomas provides a less toxic alternative to that of previous studies of preirradiation chemotherapy with these agents and merits further investigation.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/drug therapy , Cranial Irradiation , Glioma/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Brain Neoplasms/mortality , Brain Neoplasms/radiotherapy , Carmustine/administration & dosage , Carmustine/adverse effects , Cisplatin/administration & dosage , Cisplatin/adverse effects , Combined Modality Therapy , Dose Fractionation, Radiation , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Glioma/mortality , Glioma/radiotherapy , Humans , Male , Middle Aged , Survival RateABSTRACT
PURPOSE: We conducted a Phase I study of bischloroethylnitrosourea (BCNU), cisplatin, and oral etoposide administered prior to and during accelerated hyperfractionated radiation therapy in newly diagnosed high-grade glioma. Pharmacokinetic studies of oral etoposide were also done. METHODS AND MATERIALS: Patients started chemotherapy after surgery but prior to definitive radiation therapy (160 cGy twice daily x 15 days; 4800 cGy total). Initial chemotherapy consisted of BCNU 40 mg/m2 days 1-3, cisplatin 30 mg/m2 days 1-3 and 29-31, and etoposide 50 mg orally days 1-14 and 29-42, repeated in 8 weeks concurrent with radiation therapy. BCNU 200 mg/m2 every 8 weeks x 4 cycles was given after radiation therapy. RESULTS: Sixteen patients, 5 with grade 3 anaplastic astrocytoma and 11 with glioblastoma were studied. Grade 3-4 leukopenia (38%) and thrombocytopenia (31%) were dose-limiting. Other toxicities were anorexia (81%), nausea (94%), emesis (56%), alopecia (88%), and ototoxicity (38%). The maximum tolerated dose was BCNU 40 mg/m2 days 1-3, cisplatin 20 mg/m2 days 1-3 and 29-31, and oral etoposide 50 mg days 1-21 and 29-49 prior to radiation therapy and repeated in 8 weeks with the start of radiation therapy followed by BCNU 200 mg/m2 every 8 weeks for 4 cycles. Median time to progression and survival were 13 and 14 months respectively. Responses occurred in 2 of 9 (22%) patients with evaluable disease. In pharmacokinetic studies, all patients achieved plasma concentrations of >0.1 microg/ml etoposide (the in vitro radiosensitizing threshold), following a 50 mg oral dose. The mean +/- SD 2 hr and 6 hr plasma concentrations were 0.92 +/- 0.43 microg/ml and 0.36 +/- 0.12 microg/ml, respectively. Estimated duration of exposure to >0.1 microg/ml etoposide was 10-17 hr. CONCLUSIONS: Preirradiation chemotherapy with BCNU, cisplatin, and oral etoposide with accelerated hyperfractionated radiation therapy in high-grade gliomas is feasible and merits further investigation. Sustained radiosensitizing concentrations can be achieved with low oral doses of etoposide.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Brain Neoplasms/drug therapy , Glioma/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Bone Marrow/drug effects , Brain Neoplasms/metabolism , Brain Neoplasms/radiotherapy , Carmustine/administration & dosage , Carmustine/adverse effects , Carmustine/pharmacokinetics , Cisplatin/administration & dosage , Cisplatin/adverse effects , Cisplatin/pharmacokinetics , Combined Modality Therapy , Drug Administration Schedule , Etoposide/administration & dosage , Etoposide/adverse effects , Etoposide/pharmacokinetics , Female , Glioma/metabolism , Glioma/radiotherapy , Humans , Male , Middle Aged , Survival AnalysisABSTRACT
BACKGROUND: Peroneal neuropathies in patients with systemic cancer previously have been attributed to weight loss, but to the authors' knowledge other associated conditions have not been assessed, and the outcome of peroneal neuropathies in cancer patients has not been studied. METHODS: A retrospective chart review of patients evaluated at the Mayo Clinic between 1984 and 1993 with systemic malignant disease and a clinical diagnosis of peroneal neuropathy was performed to define factors associated with peroneal neuropathies and to assess outcome. All patients underwent neurologic examination and electromyography. RESULTS: Fifty-eight patients with systemic malignant disease were found to have a peroneal neuropathy. Peroneal neuropathies occurred more often in men (45 patients) than in women (13 patients). The median age of the patients was 70 years. The most common cancers were hematologic (12 patients) and pulmonary (11 patients), followed by tumors of the prostate (8 patients), gastrointestinal tract (7 patients), transitional cell (5 patients), breast (5 patients), and colon (5 patients), as well as sarcomas and melanoma (5 patients). The median time to the diagnosis of peroneal neuropathy after the diagnosis of cancer was 5 months. At the time of diagnosis, 34 patients had severe deficits, 19 had moderate deficits, and 5 had mild deficits. Associated factors included weight loss (occurring in 60% of patients), leg crossing (35% of patients), recent chemotherapy (16% of patients), cutaneous vasculitis (5% of patients), and local metastatic lesions (3% of patients). In nearly 50% of patients, peroneal neuropathy improved (25.9%) or resolved (22.4%). In 39.7% of patients, follow-up was inadequate because death occurred soon after diagnosis. Of the patients with adequate follow-up before death, 80% had either improvement (42.9%) or resolution (37.1%). CONCLUSIONS: For those patients with systemic malignant disease in whom peroneal neuropathy develops, the outcome of the neuropathy is good, with the majority of patients achieving partial or complete resolution.
Subject(s)
Neoplasms/complications , Paraneoplastic Syndromes/etiology , Peripheral Nervous System Diseases/etiology , Peroneal Nerve/physiopathology , Adult , Aged , Antineoplastic Agents/therapeutic use , Breast Neoplasms/complications , Carcinoma, Transitional Cell/complications , Colonic Neoplasms/complications , Electromyography , Female , Follow-Up Studies , Gastrointestinal Neoplasms/complications , Hematologic Neoplasms/complications , Humans , Lung Neoplasms/complications , Male , Melanoma/complications , Middle Aged , Neurologic Examination , Posture/physiology , Prognosis , Prostatic Neoplasms/complications , Retrospective Studies , Sarcoma/complications , Sex Factors , Skin Diseases, Vascular/complications , Time Factors , Vasculitis/complications , Weight LossABSTRACT
PURPOSE: The effect of radiotherapy on the long-term cognitive performance of patients treated for intracranial neoplasm is a major concern to clinicians and patients, particularly as long-term survival or cure is possible for a small minority of patients. To assess the effects of cranial radiotherapy and chemotherapy on the cognitive performance of high-grade glioma patients, we analyzed cognitive performance data collected in a series of prospective clinical trials. METHODS: We studied 701 high-grade brain tumor patients entered onto two consecutive North Central Cancer Treatment Group (NCCTG) randomized treatment trials designed to compare radiotherapy and carmustine (BCNU) versus radiotherapy and 1-(2-chloroethyl)-3(2,6 dioxo-l-piperidyl)-1-nitrosource a (PCNU) (first trial) and radiotherapy and BCNU and interferon alfa (IFN) versus radiotherapy and BCNU (second trial). Folstein Mini-Mental Status Exam (MMSE) score and Eastern Cooperative Oncology Group (ECOG) performance score (PS) recorded at baseline and 6, 12, 18, and 24 months were analyzed to assess cognitive and physical function over time. Patients who did not demonstrate tumor progression within 60 days of the assessment time were considered nonprogressors at that evaluation. A loss of greater than 3 points on the MMSE was considered significant deterioration. RESULTS: The number of patients who experienced a greater than 3-point decrease in MMSE from baseline was 13 of 119 nonprogressors (10.9%; 95% confidence interval [CI], 6.3% to 18.9%) at 6 months, three of 54 nonprogressors (5.5%; 95% CI, 0.5% to 12.8%) at 12 months, three of 30 nonprogressors (10%; 95% CI, 2.1% to 26.5%) at 18 months, and four of 22 nonprogressors (18.2%; 95% CI, 5.2% to 40.3%) at 24 months. The CIs at all times overlapped, which indicates no statistically significant increase in the percentage of patients who experienced a significant decrease in their MMSE score. Patients who demonstrated a significant decrease in their MMSE score were significantly older than those who did not (P = .0017) at 6 months and remained so throughout follow-up; moreover, they had a significantly shorter time to progression and death. ECOG PS was strongly negatively correlated with MMSE score throughout the study, and MMSE score at all time intervals was correlated with baseline PS. CONCLUSION: In this population of glioma patients who received radiotherapy, there is no clear trend to cognitive worsening. Factors such as older age, poorer PS, and subclinical tumor progression may be more significant factors in those patients who did demonstrate a significant cognitive decline.
Subject(s)
Brain Neoplasms/therapy , Cognition/drug effects , Cognition/radiation effects , Glioma/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Alkylating/administration & dosage , Brain Neoplasms/mortality , Carmustine/administration & dosage , Cranial Irradiation/adverse effects , Disease Progression , Female , Glioma/mortality , Humans , Intelligence Tests , Interferon-alpha/administration & dosage , Male , Middle Aged , Nitrosourea Compounds/administration & dosage , Prospective Studies , Survival RateABSTRACT
Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 x 10(6) units/m2 subcutaneously days 3 to 7) and eflornithine (2.25 g/m2 QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24%) were stable for more than six months, but the disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha plus eflornithine demonstrated no definite antitumor effects in this trial.
Subject(s)
Eflornithine/therapeutic use , Glioma/drug therapy , Interferon Type I/therapeutic use , Neoplasm Recurrence, Local/drug therapy , Adult , Aged , Disease Progression , Drug Therapy, Combination , Eflornithine/adverse effects , Female , Glioma/pathology , Glioma/therapy , Humans , Interferon Type I/adverse effects , Male , Middle Aged , Recombinant Proteins , Survival Analysis , Treatment OutcomeABSTRACT
PURPOSE: A Phase I study to determine the safety, toxicity, and maximum tolerated dose (MTD) of carmustine (BCNU) and interferon alpha-2a (IFN-a) when combined with radiation as initial therapy in high-grade glioma. METHODS AND MATERIALS: Patients with newly diagnosed Grade 3 or 4 astrocytoma, oligoastrocytoma, or gliosarcoma were enrolled after surgery. All received radiation therapy to the brain (64.8 Gy/36 fractions), combined with a single dose of BCNU (200 mg/m2) at the start of radiation. Chemotherapy after completing radiation consisted of BCNU 150 mg/m2 once every 7 weeks, and IFN-a 12 x 10(6) units/m2 subcutaneously Days 1-3 each week of a 7-week cycle. Subsequent dose modification was based on constitutional symptoms for IFN-a and on myelosuppression for BCNU. RESULTS: Fifteen patients were entered on the study. Four were excluded because they did not receive IFN-a (3 refused treatment and 1 patient left the study due to multiple medical problems). Eleven were evaluable for toxicity and efficacy. Nonhematological toxicity, mainly lethargy and flu-like symptoms, were dose-limiting for IFN-a. After the first 6 patients were treated per the initial protocol, the frequency of IFN-a administration was decreased to Days 1-3 on weeks 1, 3, and 5 of the 7-week cycle for 5 additional patients. Lethargy, fever, chills, myalgias, alopecia, and anorexia occurred in all patients. Other toxicities included nausea and vomiting (91%), central-nervous-system depression or mood changes (64%), headaches (55%), and elevation of liver enzymes (36%). Grade 3-4 leukopenia occurred in 4 (45%) of 11 patients, and Grade 3-4 thrombocytopenia in 3 (27%) of 11 patients. Due to myelosuppressive effects, BCNU dose was not escalated. Median survival of the cohort was 44 months. Objective responses occurred in 5 (56%) of 9 patients and median duration of response was 33 months. The MTD of this combination after radiation therapy is IFN-a 12 x 10(6) units/m2 Days 1-3, on Weeks 1, 3, and 5 of a 7-week cycle and BCNU 150 mg/m2 Day 1, every 7 weeks. CONCLUSIONS: Treatment with radiation, IFN-a, and BCNU is feasible and effective in patients with high-grade gliomas, although constitutional symptoms from IFN-a are substantial.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Glioma/drug therapy , Glioma/radiotherapy , Adult , Aged , Brain Neoplasms/pathology , Carmustine/administration & dosage , Carmustine/adverse effects , Combined Modality Therapy , Female , Glioma/pathology , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Male , Middle Aged , Radiotherapy/adverse effects , Recombinant Proteins , Survival AnalysisABSTRACT
OBJECTIVE: To study the relative utility of computed tomography (CT) and magnetic resonance imaging (MRI) of the lumbosacral plexus in patients with systemic cancer and plexopathy. DESIGN: In a retrospective study, we identified all patients encountered at Mayo Clinic Rochester between 1987 and 1993 with a diagnosis of lumbosacral plexopathy, and we selected for analysis those with MRI scans of the plexus (an abnormal finding was not necessary for inclusion) and a clinical and electrophysiologic appearance consistent with a diagnosis of metastatic lumbosacral plexopathy. MATERIAL AND METHODS: The study group consisted of 31 patients (20 men and 11 women). The types of tumor were as follows: prostatic, 10 patients; colorectal, 7; bladder, 3; cervical, 3; and other, 8. Eighteen patients had received pelvic radiotherapy before diagnosis of lumbosacral plexopathy. All available MRI scans (in 27 patients) were reviewed blinded; the initial imaging report was used if the actual scans were unavailable (in 4). CT had been done in 22 patients, and results for 16 were available for blinded review. Original reports were available for the other six. RESULTS: Direct involvement of the lumbosacral plexus by tumor was evident on 23 MRI studies, and 6 others showed widespread metastatic disease in the region of the plexus. On 13 CT examinations, direct involvement of the lumbosacral plexus by tumor was noted. In four patients, MRI findings were abnormal and CT findings were normal. No patient had abnormal CT findings and normal MRI findings. CONCLUSION: In this retrospective review, MRI was more sensitive than CT for diagnosing cancer-induced lumbosacral plexopathy. Thus, use of MRI should be considered in the diagnostic work-up of patients with clinical and electrophysiologic evidence of plexopathy and suspected systemic cancer.
Subject(s)
Lumbosacral Plexus , Magnetic Resonance Imaging , Neoplasms/diagnosis , Peripheral Nervous System Diseases/etiology , Diagnosis, Differential , Female , Humans , Lumbosacral Plexus/diagnostic imaging , Lumbosacral Plexus/pathology , Male , Middle Aged , Neoplasms/complications , Neoplasms/diagnostic imaging , Neoplasms/pathology , Peripheral Nervous System Diseases/diagnostic imaging , Peripheral Nervous System Diseases/pathology , Retrospective Studies , Tomography, X-Ray ComputedABSTRACT
PURPOSE: A minority of cancer survivors develops long-term postsurgical neuropathic pain. Based on evidence that capsaicin, the pungent ingredient in hot chili peppers, might be useful for treating neuropathic pain, we developed the present clinical trial. PATIENTS AND METHODS: Ninety-nine assessable patients with postsurgical neuropathic pain were entered onto this study. After stratification, patients were to receive 8 weeks of a 0.075% capsaicin cream followed by 8 weeks of an identical-appearing placebo cream, or vice versa. A capsaicin/placebo cream was to be applied to the painful site four times daily. Treatment evaluation was performed by patient-completed weekly questionnaires. RESULTS: During the first 8-week study period, the capsaicin-cream arm was associated with substantially more skin burning, skin redness, and coughing (P < .0001 for each). Nonetheless, treatment was stopped for patient refusal or toxicity just as often while patients were receiving the placebo as compared with the capsaicin. The capsaicin cream arm had substantially more pain relief (P = .01) after the first 8 weeks, with an average pain reduction of 53% versus 17%. On completion of the 16-week study period, patients were asked which treatment period was most beneficial. Of the responding patients, 60% chose the capsaicin arm, 18% chose the placebo arm, and 22% chose neither (P = .001). CONCLUSION: A topical capsaicin cream decreases postsurgical neuropathic pain and, despite some toxicities, is preferred by patients over a placebo by a three-to-one margin among those expressing a preference.
Subject(s)
Capsaicin/administration & dosage , Neoplasms/surgery , Neuralgia/drug therapy , Pain, Postoperative/drug therapy , Administration, Topical , Aged , Capsaicin/adverse effects , Double-Blind Method , Female , Humans , Male , Middle Aged , Neuralgia/etiology , Ointments , Pain MeasurementABSTRACT
Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin. There were three responses seen. Toxicity consisted of stomatitis, diarrhea, and hematological suppression. 5-fluorouracil and leucovorin would appear to be minimally effective in recurrent brain tumors.
Subject(s)
Antidotes/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , Astrocytoma/drug therapy , Brain Neoplasms/drug therapy , Fluorouracil/therapeutic use , Leucovorin/therapeutic use , Oligodendroglioma/drug therapy , Adult , Aged , Antidotes/toxicity , Antimetabolites, Antineoplastic/toxicity , Female , Fluorouracil/toxicity , Humans , Leucovorin/toxicity , Leukopenia/chemically induced , Male , Middle Aged , Recurrence , Stomatitis/chemically induced , Thrombocytopenia/chemically inducedABSTRACT
OBJECTIVE: To describe the clinical course, survival, resource use, and direct medical costs of care for patients with high-grade astrocytomas. MATERIAL AND METHODS: All patients with grade 3 or 4 astrocytoma who resided in Olmsted County, Minnesota, or one of the six adjacent counties and had a tissue diagnosis first made between 1987 and 1992 were studied. Clinical characteristics, initial management, use of resources, clinical course, survival, and medical charges were analyzed. RESULTS: Sixty-four patients, with a mean age of 62 years, were identified; 81% had glioblastoma multiforme. Approximately 60% underwent surgical resection, 80% had radiotherapy, and 50% had chemotherapy for initial management. After initial treatment (median duration, 116 days), approximately 75% of patients had a course with stable disease (median duration, 198 days). The overall median duration of survival was 323 days; lower grade and younger age were significantly associated with longer median survival-for example, 1,493 days for patients younger than 65 years with grade 3 astrocytomas and 205 days for patients 65 years old or older with grade 4 astrocytomas. The mean total direct medical charges were $67,887. CONCLUSION: In most patients with high-grade astrocytomas, a substantial period elapsed before disease progressed. Although the overall median duration of survival was less than 1 year, younger patients, especially those with grade 3 astrocytomas, had a longer survival. The management of patients with high-grade astrocytomas uses substantial health-care resources.
Subject(s)
Astrocytoma , Brain Neoplasms , Adult , Aged , Aged, 80 and over , Astrocytoma/economics , Astrocytoma/mortality , Astrocytoma/therapy , Brain Neoplasms/economics , Brain Neoplasms/mortality , Brain Neoplasms/therapy , Combined Modality Therapy , Costs and Cost Analysis , Female , Humans , Male , Middle Aged , Retrospective Studies , Survival Analysis , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Brain metastases occur in 25% to 35% of all cancer patients, with colorectal carcinoma accounting for approximately 8% of these. Information about patients with brain metastases from colorectal carcinoma is limited, with the largest previous series reporting only 40 patients. To date there have been no reports describing the subgroup of patients with long term survival ( > 1 yr). METHODS: A retrospective review of 150 patients seen at the Mayo Clinic between 1976 and 1993 with pathologic (56) and/or radiographic (94) confirmation of brain metastases from colorectal carcinoma is presented. RESULTS: The majority of patients (82%) with brain metastases from colorectal carcinoma have concomitant extracerebral metastases, especially in the lungs. Only 16% of the patients survived > 1 year after diagnosis (4 > 4 yrs., 2 > 10 yrs). Of these, 92% had single cerebral metastases and 38% had no systemic metastases. In addition, young age and the absence of bony metastases or memory loss were associated with increased survival. Median survival for all of the patients receiving surgery and radiotherapy (39), surgery alone (11), radiotherapy alone (79) and supportive care (17) are 42, 45, 16, and 8 weeks, respectively. Thirty percent of the patients treated with radiotherapy showed regression of their tumors on follow-up head scans; three had complete regression. CONCLUSIONS: One-year survivors of brain metastases from colorectal carcinoma were uncommon, accounting for 16% of the patients and most of these (92%) had solitary lesions. Nineteen of 24 long term survivors had surgical resection as part of their treatment. Given the similar results in patients treated with surgery plus radiotherapy and those treated with surgery alone, as well as the potential long term side effects of radiotherapy, withholding radiotherapy for those patients with the possibility of long term survival should be considered.
Subject(s)
Brain Neoplasms/secondary , Colorectal Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Time FactorsABSTRACT
Radiotherapy is effective for most cases of spinal cord compression. Although recurrent spinal cord compression is a common problem, little is known about whether reirradiation preserves neurologic function and what risk of radiation myelopathy it carries. To investigate this question, we reviewed patients at the Mayo Clinic between 1975 and 1992 undergoing two or more courses of radiotherapy to the same segment of the spinal column with radiographically documented epidural disease at the time of reirradiation to determine outcome as measured by the ability to walk and by survival. Fifty-four patients met the study criteria. Radiation doses for the first course ranged from 2,250 to 5,400 cGy (median, 3,000 cGy), and total dose for all courses to the reirradiated spinal segment ranged from 3,650 to 8,089 cGy (median, 5,425 cGy). All patients were ambulatory following the first course of radiation, 40 (74%) were ambulatory at the onset of reirradiation, and 42 (78%) were ambulatory at the end of reirradiation. Thirty-seven patients (69%) remained ambulatory at their last follow-up 6 days to 80 months following reirradiation (median, 4.7 months). Five patients eventually became nonambulatory 6.5 to 35 months following reirradiation. Median survival for all patients following reirradiation was 4.2 months. We conclude that for cancer patients with progressive epidural disease following radiotherapy, reirradiation frequently preserves ambulation and carries minimal risk of radiation myelopathy during the patients' lifetime.
Subject(s)
Epidural Neoplasms/radiotherapy , Spinal Cord Compression/radiotherapy , Adult , Aged , Aged, 80 and over , Epidural Neoplasms/complications , Epidural Neoplasms/physiopathology , Epidural Neoplasms/secondary , Female , Humans , Male , Middle Aged , Spinal Cord Compression/etiology , Spinal Cord Compression/physiopathology , Treatment OutcomeABSTRACT
The goal of this study was to determine the antitumor activity and toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) plus recombinant interferon-alpha (IFN-alpha) in patients with recurrent glioma. As single agents, both BCNU and IFN-alpha can cause tumor regression in patients with recurrent glioma. In vitro studies suggest synergy between the two agents. Thirty-five patients in whom computerized tomography (CT) or magnetic resonance (MR) evidence was obtained of progressive astrocytoma, oligoastrocytoma, or oligodendroglioma received recombinant IFN-alpha 2a (12 x 10(6) U/m2 intramuscularly) on Days 1 through 3 and BCNU (150 mg/m2 intravenously) on Day 3 of each 6-week cycle. All patients had tumor progression despite radiation therapy and had received no prior chemotherapy. Response was assessed by CT or MR evidence and by neurological examination while the patients were on a regimen of stable or decreasing doses of corticosteroids. All patients could be evaluated for response and toxicity. Twenty-nine percent of the patients demonstrated objective tumor regression; 37% remained stable for more than 6 months and 25% were stable for less than 6 months. The median duration of response to IFN-alpha and BCNU was 9.9 months and the median survival for all patients was 13.3 months. Toxicity consisted primarily of moderate myelosuppression, venous irritation, vomiting, flulike symptoms, and transient reversible exacerbation of underlying neurological symptoms. The use of BCNU plus IFN-alpha is a safe, active regimen in the treatment of patients with recurrent glioma who have failed to respond to prior radiation therapy. The contribution of IFN to the antitumor activity observed in this study compared with that previously described with BCNU alone cannot be assessed from this trial.
Subject(s)
Brain Neoplasms/therapy , Carmustine/therapeutic use , Glioma/therapy , Interferon-alpha/therapeutic use , Neoplasm Recurrence, Local/therapy , Adult , Aged , Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Combined Modality Therapy , Female , Glioma/drug therapy , Glioma/mortality , Humans , Interferon alpha-2 , Male , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/mortality , Prognosis , Recombinant Proteins , Regression Analysis , Remission Induction , Survival Rate , United StatesABSTRACT
Fifty-one patients with supratentorial glioma treated with external beam radiotherapy (median dose 59.5 Gy) who then demonstrated clinical or radiographic evidence of disease progression underwent stereotactic biopsy to differentiate tumor recurrence from radiation necrosis. The original tumor histological type was diffuse or fibrillary astrocytoma in 21 patients (41%), oligodendroglioma in 13 (26%), and oligoastrocytoma in 17 (33%); 40 tumors (78%) were low-grade (Kernohan Grade 1 or 2). The median time to suspected disease progression was 28 months. Stereotactic biopsy showed tumor recurrence in 30 patients (59%), radiation necrosis in three (6%), and a mixture of both in 17 (33%); one patient (2%) had a parenchymal radiation-induced chondroblastic osteosarcoma. The tumor type at stereotactic biopsy was similar to the original tumor type and was astrocytoma in 24 patients (47%), oligodendroglioma in eight (16%), oligoastrocytoma in 16 (31%), unclassifiable in two (4%), and chondroblastic osteosarcoma in one patient (2%). At biopsy, however, only 19 tumors (37%) were low grade (Kernohan Grade 1 or 2). Subsequent surgery confirmed the stereotactic biopsy histological findings in eight patients. Follow-up examination showed 14 patients alive with a median survival of 1 year for the entire group. Median survival times after biopsy were 0.83 year for patients with tumor recurrence and 1.86 years for patients with both tumor recurrence and radionecrosis; these findings were significantly different (p = 0.008, log-rank test). No patient with radiation necrosis alone died. Other factors associated with reduced survival were a high proportion of residual tumor (p = 0.024), a low proportion of radionecrosis (p < 0.001), and a Kernohan Grade of 3 or 4 (p = 0.005). In conclusion, in patients with previously irradiated supratentorial gliomas in whom radionecrosis or tumor recurrence was clinically or radiographically suspected, results of stereotactic biopsy could be used to differentiate tumor recurrence, radiation necrosis, a mixture of both lesions, or radiation-induced neoplasm. In addition, biopsy results could predict survival rates.
Subject(s)
Brain Neoplasms/diagnosis , Brain/radiation effects , Glioma/diagnosis , Neoplasm Recurrence, Local/diagnosis , Radiation Injuries/diagnosis , Radiotherapy/adverse effects , Adult , Analysis of Variance , Biopsy/methods , Brain/pathology , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Diagnosis, Differential , Female , Glioma/mortality , Glioma/pathology , Glioma/radiotherapy , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Necrosis , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Radiation Injuries/etiology , Radiation Injuries/pathology , Stereotaxic Techniques , Survival Rate , Tomography, X-Ray ComputedABSTRACT
Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.
Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Glioma/drug therapy , Imides/therapeutic use , Isoquinolines/therapeutic use , Adenine , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Antineoplastic Agents/adverse effects , Astrocytoma/drug therapy , Astrocytoma/surgery , Brain Neoplasms/pathology , Brain Neoplasms/surgery , Combined Modality Therapy , Female , Glioma/pathology , Glioma/surgery , Humans , Imides/adverse effects , Isoquinolines/adverse effects , Male , Middle Aged , Naphthalimides , Nervous System Diseases/chemically induced , Nervous System Diseases/drug therapy , Oligodendroglioma/drug therapy , Oligodendroglioma/surgery , Organophosphonates , Recurrence , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
Among 5,058 patients seen at the Mayo Clinic from 1976 through 1990 for face pain, we diagnosed trigeminal neuralgia in 2,972. Tumors were causing the face pain in 296 patients. Sex and pain distributions paralleled those in idiopathic trigeminal neuralgia; however, patients with tumors causing trigeminal neuralgia were younger than those with idiopathic pain. Meningiomas and posterior fossa tumors were the most common. Neurologic deficits developed on follow-up evaluation in 47% of the patients, often precipitating further study and eventual diagnosis of the tumor. Delay in tumor diagnosis averaged 6.3 years. CT with contrast was the most frequently used initial diagnostic radiographic technique, detecting a tumor in 40 of 43 examinations. MRI was subsequently used to confirm and better delineate the tumor in five of five cases. Carbamazepine was the most effective drug for relieving trigeminal neuralgia, but relief was usually temporary. Of the surgical treatment options, total removal of the tumor was the most effective in completely relieving tic pain. In patients at high surgical risk, however, temporarily or permanently blocking afferent impulses with radiofrequency ablation, glycerol rhizotomy, or alcohol blocks was a good alternative to craniotomy.